Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$6.09 +0.8%	$4.88	$3.42 ▼ $7.20	$342.34M	1.82	1.52 million shs	585,162 shs
HRTX Heron Therapeutics	$2.01 -2.4%	$2.01	$1.04 ▼ $3.75	$306.65M	1.16	2.23 million shs	702,633 shs
IZTC Invizyne Technologies	$13.15 -5.8%	$12.48	$8.50 ▼ $23.00	$82.21M	N/A	37,647 shs	769 shs
RCKT Rocket Pharmaceuticals	$3.07 +1.3%	$5.62	$2.19 ▼ $26.98	$327.83M	0.68	2.04 million shs	3.28 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	+1.51%	+8.44%	+19.37%	+40.47%	+2.37%
HRTX Heron Therapeutics	-2.83%	+0.98%	+0.49%	-11.21%	-43.41%
IZTC Invizyne Technologies	0.00%	-0.48%	+3.27%	-7.21%	+1,343,549,900.00%
RCKT Rocket Pharmaceuticals	-4.11%	+3.77%	-56.71%	-64.35%	-86.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACB Aurora Cannabis	0.3866 of 5 stars	0.0	2.0	0.0	0.0	2.0	0.8	0.6
HRTX Heron Therapeutics	4.0284 of 5 stars	3.5	1.0	0.0	4.2	3.3	1.7	0.6
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	4.9578 of 5 stars	4.2	4.0	0.0	4.7	2.9	5.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	3.67	Strong Buy	N/A	N/A
HRTX Heron Therapeutics	3.00	Buy	$5.67	181.92% Upside
IZTC Invizyne Technologies	0.00	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	2.41	Hold	$19.57	537.51% Upside

Current Analyst Ratings Breakdown

Latest IZTC, RCKT, HRTX, and ACB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$320.81M	1.07	$0.23 per share	26.35	$8.18 per share	0.74
HRTX Heron Therapeutics	$148.52M	2.06	N/A	N/A	($0.23) per share	-8.74
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	-$48.62M	$0.05	121.82	13.84	N/A	0.42%	0.59%	0.42%	6/18/2025 (Estimated)
HRTX Heron Therapeutics	-$110.56M	-$0.06	N/A	N/A	N/A	-20.31%	N/A	-12.72%	8/5/2025 (Estimated)
IZTC Invizyne Technologies	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	8/4/2025 (Estimated)

Latest IZTC, RCKT, HRTX, and ACB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/18/2025	Q4 2025	ACB Aurora Cannabis	$0.11	N/A	N/A	N/A	$88.85 million	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/6/2025	Q1 2025	HRTX Heron Therapeutics	-$0.01	$0.01	+$0.02	$0.01	$37.08 million	$38.90 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.07	3.30	1.60
HRTX Heron Therapeutics	N/A	2.28	1.74
IZTC Invizyne Technologies	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
HRTX Heron Therapeutics	80.01%
IZTC Invizyne Technologies	N/A
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
HRTX Heron Therapeutics	5.86%
IZTC Invizyne Technologies	N/A
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,340	56.21 million	54.85 million	Optionable
HRTX Heron Therapeutics	300	152.56 million	143.33 million	Optionable
IZTC Invizyne Technologies	29	6.25 million	N/A	N/A
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable

IZTC, RCKT, HRTX, and ACB Headlines

Recent News About These Companies

Join Class Action to Recover Losses from Rocket Pharmaceuticals, Inc. (RCKT) - Contact Levi & Korsinsky Before August 11, 2025

June 12 at 6:35 PM | accessnewswire.com

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

June 12 at 5:46 PM | prnewswire.com

Rocket Investor Sues After Rare Disease’s Therapy Trial Halted

June 12 at 5:27 PM | news.bloomberglaw.com

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Urged to Join Class Action Before August 11, 2025 - Contact Levi & Korsinsky

June 12 at 5:15 PM | accessnewswire.com

RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit

June 12 at 4:48 PM | prnewswire.com

August 11, 2025 Deadline Approaching: Join Class Action Against Rocket Pharmaceuticals, Inc. (RCKT) - Contact Levi & Korsinsky

June 12 at 4:20 PM | accessnewswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman

June 12 at 3:40 PM | globenewswire.com

Levi & Korsinsky Urges Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Act Before Lead Plaintiff Deadline August 11, 2025

June 12 at 3:00 PM | accessnewswire.com

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Rocket Pharmaceuticals, Inc. (RCKT)

June 12 at 2:44 PM | globenewswire.com

Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

June 12 at 1:30 PM | businesswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before August 11, 2025

June 12 at 10:30 AM | accessnewswire.com

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

June 12 at 10:29 AM | globenewswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

June 12 at 10:00 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

June 12 at 9:00 AM | prnewswire.com

Cantor Fitzgerald Estimates RCKT FY2026 Earnings

June 12 at 2:23 AM | americanbankingnews.com

Securities Fraud Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - Levi & Korsinsky Reminds Investors of August 11, 2025

June 12 at 2:15 AM | accessnewswire.com

Shareholder Alert: Robbins LLP Informs Investors of the Rocket Pharmaceuticals, Inc. Class Action

June 12 at 1:44 AM | prnewswire.com

Rocket Classic 2025 Boasts ‘Most Competitive and Exciting Field’ Yet as Big Names Commit

June 11 at 10:14 PM | msn.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Rocket Pharmaceuticals, Inc. Securities and Sets a Lead Plaintiff Deadline of August 11, 2025

June 11 at 8:09 PM | globenewswire.com

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Investigation

June 11 at 10:30 AM | accessnewswire.com

Cantor Fitzgerald Forecasts RCKT FY2026 Earnings

June 10 at 8:30 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC, RCKT, HRTX, and ACB Company Descriptions

Aurora Cannabis NASDAQ:ACB

$6.09 +0.05 (+0.83%)

As of 04:00 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Heron Therapeutics NASDAQ:HRTX

$2.01 -0.05 (-2.43%)

As of 04:00 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Invizyne Technologies NASDAQ:IZTC

$13.15 -0.81 (-5.77%)

As of 06/11/2025

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.07 +0.04 (+1.32%)

As of 04:00 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time